Cost-Effectiveness Analysis of the Adjunctive Therapy of Ivabradine for the Treatment of Heart Failure with Reduced Ejection Fraction

References

• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–2200. doi:10.1093/eurheartj/ehw12827206819
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70(6):776–803. doi:10.1016/j.jacc.2017.04.02528461007
   PubMed Web of Science ®Google Scholar
• Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875–885. doi:10.1016/S0140-6736(10)61198-120801500
   PubMed Web of Science ®Google Scholar
• DiFrancesco D. Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol Res. 2006;53(5):399–406. doi:10.1016/j.phrs.2006.03.00616638640
   PubMed Web of Science ®Google Scholar
• Pocock SJ, Wang D, Pfeffer MA, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006;27(1):65–75. doi:10.1093/eurheartj/ehi55516219658
   PubMed Web of Science ®Google Scholar
• Fox K, Ford I, Steg PG, et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet. 2008;372(9641):817–821. doi:10.1016/S0140-6736(08)61171-X18757091
   PubMed Web of Science ®Google Scholar
• Flannery G, Gehrig-Mills R, Billah B, Krum H. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol. 2008;101(6):865–869. doi:10.1016/j.amjcard.2007.11.02318328855
   PubMedGoogle Scholar
• Griffiths A, Paracha N, Davies A, Branscombe N, Cowie MR, Sculpher M. The cost effectiveness of ivabradine in the treatment of chronic heart failure from the UK national health service perspective. Heart. 2014;100:1031–1036. doi:10.1136/heartjnl-2013-30459824634022
   PubMed Web of Science ®Google Scholar
• Kourlaba G, Parissis J, Karavidas A, et al. Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece. BMC Health Serv Res. 2014;14:631. doi:10.1186/s12913-014-0631-025496716
   PubMed Web of Science ®Google Scholar
• Adena MA, Hamann G, Sindone AP. Cost-effectiveness of ivabradine in the treatment of chronic heart failure. Heart Lung Circ. 2018:28;1–9.
   Web of Science ®Google Scholar
• Krittayaphong R, Permsuwan U. Cost-effectiveness analysis of sacubitril-valsartan compared with enalapril in patients with heart failure with reduced ejection fraction in Thailand. Am J Cardiovasc Drugs. 2018:18(5);1–9.29280064
   PubMed Web of Science ®Google Scholar
• Tanvejsilp P, Ngorsuraches S. Defining the scope of health technology assessment and types of health economic evaluation. J Med Assoc Thai. 2014;97(Suppl 5):S10–6.
   PubMedGoogle Scholar
• Janwanishstaporn S. National trend, in-hospital and long term outcomes in the hospitalized heart failure patients in Thailand. Thai Heart J. 2015;28:128.
   Google Scholar
• Krum H, Sindone A. Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate ≥77 bpm: subgroup analysis of SHIFT. Heart Lung Circ. 2013;22(Suppl 1):S87–S88. doi:10.1016/j.hlc.2013.05.208
   Google Scholar
• Bundhamcharoen K, Aungkulanon S. Burden of disease in Thai population 2009. Int Health Policy Program. 2012.
   Google Scholar
• Health Statistics Strategy and Planning Division, Ministry of Public Health. Mortality rate per 100,000 Thai population by causes of death during 1998–2016; 2016 [updated 710, 2018] Available from: http://social.nesdb.go.th/SocialStat/StatReport_Final.aspx?reportid=441&template=2R1C&yeartype=M&subcatid=15.
   Google Scholar
• Komajda M, Tavazzi L, Swedberg K, et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. Eur J Heart Fail. 2016;18:1182–1189. doi:10.1002/ejhf.58227210035
   PubMed Web of Science ®Google Scholar
• Drug and Medical Supply Information Center, Ministry of Public Health; 2018 [updated 712, 2018] Available from: http://dmsic.moph.go.th.
   Google Scholar
• Riewpaiboon A. Measurement of costs for health economic evaluation. J Med Assoc Thai. 2014;97(Suppl 5):S17–26.
   PubMedGoogle Scholar
• National Drug System Development Committee. Medium Drug Price Announcement. Bangkok: Royal Gazette in Thailand; 2018.
   Google Scholar
• Permsuwan U, Guntawongwan K, Buddhawongsa P. Handling time in economic evaluation studies. J Med Assoc Thai. 2014;97(Suppl 5):S50–S58.
   PubMedGoogle Scholar
• Limwattananon S. Sensitivity analysis for handling uncertainty in an economic evaluation In: Chaikledkaew U, Teerawattananon Y, editors. Guidelines for Health Technology Assessment in Thailand. 2nd ed. Nonthaburi: Wacharin; 2013:105–119.
   Google Scholar
• Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17(5):479–500. doi:10.2165/00019053-200017050-0000610977389
   PubMed Web of Science ®Google Scholar
• Zethraeus N, Johannesson M, Jönsson B, Löthgren M, Tambour M. Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies. Pharmacoeconomics. 2003;21(1):39–48. doi:10.2165/00019053-200321010-0000312484802
   PubMed Web of Science ®Google Scholar
• Kansal AR, Cowie MR, Kielhorn A, et al. Cost-effectiveness of ivabradine for heart failure in the United States. J Am Heart Assoc. 2016;5:e003221. doi:10.1161/JAHA.116.00322127153871
   PubMedGoogle Scholar